The shares of one of the leading Indian pharmaceutical companies, which operates in CDMO, complex hospital generics, and consumer healthcare, fell up to 3% on Friday after reports said a U.S.-based private equity firm is planning to sell up to a 10% stake.
With a market capitalization of Rs 27,030 Crores, the share price of Piramal Pharma Limited was trading almost 3% down to hit an intraday low of Rs 197.05 per share from its previous closing price of Rs 202.40 per share.
Stake Sale
Piramal Pharma Ltd, part of the Piramal Group, traded nearly 3% lower on Friday, July 5, after reports said U.S.-based Carlyle Group is planning to sell up to a 10% stake through block deals worth Rs 2,600 to Rs 2,700 crore.
Carlyle had acquired a 20% stake in the company in June 2020 for around Rs 3,523 crore. As of March 31, 2025, it held an 18% stake through its affiliate CA Alchemy Investments. Financial services firm Motilal Oswal has been appointed to handle the block deal process.
Piramal Pharma Ltd (PPL), part of the Piramal Group, operates across three core segments: Contract Development and Manufacturing Organization (CDMO), Complex Hospital Generics (CHG), and India Consumer Healthcare (ICH). In FY25, all segments recorded steady growth. Revenue from CDMO rose 15% year-on-year from Rs 4,750 crore to Rs 5,447 crore, CHG grew by 7.5% from Rs 2,449 crore to Rs 2,633 crore, and ICH increased 11% from Rs 985 crore to Rs 1,093 crore.
The company maintains a strong global footprint with 17 manufacturing and development sites and a commercial presence in over 100 countries. Its CHG business alone serves more than 6,000 hospitals, reinforcing Piramal Pharma’s position as a key player in the global healthcare space.
Chairperson Guidance
Nandini Piramal, Chairperson, Piramal Pharma Limited, said, “FY25 has been a steady year for the company as we crossed $1Bn in revenues with 12 percent YoY growth accompanied by 17 percent EBITDA margin and 5x increase in Net Profits, in line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x while making regular investments in capabilities and capacities for future growth.
During the year, we progressed well on our key performance metrics such as growth in innovation-related work and differentiated capabilities in the CDMO business, maintaining our leading position in inhalation anesthetic Sevoflurane in the US market, and healthy growth in our power brands in our consumer healthcare business.
We believe we are on track to deliver on our FY2030 aspirations of becoming a $2bn revenue company with 25% EBITDA margins and high teens ROCE.” The company reported a revenue of Rs 9,151 crore in FY25, up by 12 percent from its FY24 revenue of Rs 8,171 crore. Coming to its profitability, the company reported a net profit rise of 405.6 percent to Rs 91 crore in FY25 from Rs 18 crore in FY24.
Written By Rohan Pandey
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
